Abstract

BackgroundMeasurement-guided dose reconstruction has lately attracted significant attention because it can predict the delivered patient dose distribution. Although the treatment planning system (TPS) uses sophisticated algorithm to calculate the dose distribution, the calculation accuracy depends on the particular TPS used. This study aimed to investigate the relationship between the gamma passing rate (GPR) and the clinically relevant dose–volume index based on the predicted 3D patient dose distribution derived from two TPSs (XiO, RayStation).MethodsTwenty-one breast intensity-modulated radiation therapy plans were inversely optimized using XiO. With the same plans, both TPSs calculated the planned dose distribution. We conducted per-beam measurements on the coronal plane using a 2D array detector and analyzed the difference in 2D GPRs between the measured and planned doses by commercial software. Using in-house software, we calculated the predicted 3D patient dose distribution and derived the predicted 3D GPR, the predicted per-organ 3D GPR, and the predicted clinically relevant dose–volume indices [dose–volume histogram metrics and the value of the tumor-control probability/normal tissue complication probability of the planning target volume and organs at risk]. The results derived from XiO were compared with those from RayStation.ResultsWhile the mean 2D GPRs derived from both TPSs were 98.1% (XiO) and 100% (RayStation), the mean predicted 3D GPRs of ipsilateral lung (73.3% [XiO] and 85.9% [RayStation]; p < 0.001) had no correlation with 2D GPRs under the 3% global/3 mm criterion. Besides, this significant difference in terms of referenced TPS between XiO and RayStation could be explained by the fact that the error of predicted V5Gy of ipsilateral lung derived from XiO (29.6%) was significantly larger than that derived from RayStation (− 0.2%; p < 0.001).ConclusionsGPR is useful as a patient quality assurance to detect dosimetric errors; however, it does not necessarily contain detailed information on errors. Using the predicted clinically relevant dose–volume indices, the clinical interpretation of dosimetric errors can be obtained. We conclude that a clinically relevant dose–volume index based on the predicted 3D patient dose distribution could add to the clinical and biological considerations in the GPR, if we can guarantee the dose calculation accuracy of referenced TPS.

Highlights

  • Measurement-guided dose reconstruction has lately attracted significant attention because it can predict the delivered patient dose distribution

  • The present study aims to verify the usefulness of the predicted clinically relevant dose–volume index (DVH metrics and TCP/NTCP values) based on the predicted 3D patient dose distribution by comparison with the 2D gamma passing rate (GPR), the predicted 3D GPR, and the predicted per-organ 3D GPR using the in-house Measurement-guided dose reconstruction (MGDR) software in breast intensity-modulated radiation therapy (IMRT)

  • The mean 2D GPRs calculated by commercial software were 95% or over under 3% global/3 mm criterion, the predicted per-organ 3D GPRs did not correlate with the 2D GPRs under 3% global/3 mm criterion

Read more

Summary

Introduction

Measurement-guided dose reconstruction has lately attracted significant attention because it can predict the delivered patient dose distribution. This study aimed to investigate the relationship between the gamma passing rate (GPR) and the clinically relevant dose– volume index based on the predicted 3D patient dose distribution derived from two TPSs (XiO, RayStation). The gamma passing rate (GPR), introduced by Low et al [2], conveniently combines the dose difference and the distance to agreement by considering the difference between the planned and measured dose distributions. Measurement-guided dose reconstruction (MGDR) [7,8,9] using commercial 3DVH software (Sun Nuclear Corporation, Melbourne, FL, USA) [10] has been used to predict the delivered 3D dose distribution, including potential dose error during beam delivery. With regard to the relationship between GPR and the predicted DVH metrics, Nelms et al [7] demonstrated that the GPR is not correlated with dose errors in organs at risk (OARs)

Objectives
Methods
Results
Discussion
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.